Lung Lymphoepithelial Carcinoma

SAN FRANCISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that nearly 20 accepted clinical data of its novel oncology molecules, including six oral presentations, will be released at World Conference on Lung Cancer (WCLC) from Sept 7-10, 2024, in San Diego, U.S., and the European Society of Medical Oncology (ESMO) from Sept 13-17, 2024, in Barcelona, Spain. Key data showcase includes: an oral presentation of updated Phase 1 result of its first-in-class PD-1/IL-2 α -bias (IBI363) in NSCLC (up to 3mg/kg dosage) at WCLC, updated Phase 1 results of IBI363 (PD-1/IL-2 α -bias ) combination therapy in colorectal cancer at ESMO, an oral presentation of updated pivotal Phase 2 results of Dupert® (fulzerasib, KRAS G12C inhibitor) in NSCLC at WCLC, an oral presentation of Phase 1 results of IBI354 (HER2 ADC) in HER2+ solid tumors at ESMO, and multiple clinical results of TYVYT® (sintilimab injection). Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are very pleased to present a robust set of clinical data for our next-generation innovative bispecific antibodies and ADC molecules across renowned medical conferences of 2024 including ASCO, ESMO Plenary and ESMO GI in June, and WCLC and ESMO in September. We observed the preliminary efficacy and safety signals for those innovative candidates, underscoring their potential for further development and clinical value. As one of the few biopharmaceutical companies with both the technology platforms and robust pipeline in "IO+ADC" areas, Innovent remains dedicated to advancing cancer treatment and is committed to offering doctors and patients more innovative, effective, and safe therapeutic options." Details on the abstracts are listed below: WCLC: Oral Sessions Abstract Title: First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase 1 Study Abstract No: MA11.04 Session Type and Title: WCLC 2024-MA11. Building on the Foundations of Current Immunotherapies Presentation Time: Tuesday, September 10, 2024, 13:37-13:42 PDT Presenter: Jianya Zhou,The First Affiliated Hospital of Zhejiang University School of Medicine Abstract Title: KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study Abstract No: OA14.05 Session Type and Title: WCLC 2024-OA14. New Horizons in Targeting KRAS G12C Presentation Time: Monday, September 9, 2024, 15:52-16:02 PDT Presenter: Qing Zhou, Guangdong People's Hospital Abstract Title: Neoadjuvant Sintilimab plus Chemotherapy in EGFR-mutant NSCLC Followed by adjuvant Osimertinib or Observation: A Phase 2 CTONG2104 Trial Abstract No: MA15.11 Session Type and Title: Mini Oral Presentation Time: Tuesday, September 10, 2024 at 3:48-3:53 PM PDT Presenter: Guangdong Lung Cancer Institute, C. Zhang Abstract Title: First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepithelioma-like carcinoma: A Multicenter, Single-Arm, Phase 2 Trial Abstract No: MA11.03 Session Type and Title: Mini Oral Presentation Time: Tuesday, September 10, 2024 at 1:32-1:37 PM PDT Presenter: The First Affiliated Hospital of Medical University, C. Zhou ESMO: Oral Sessions Abstract Title: IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): results from a Phase 1 study Abstract No: 345MO Session Type and Title: ESMO 2024-Mini oral session 1: Breast cancer, metastatic Presentation Time: Sunday, September 15, 2024, 9:15-9:20 AM CEST Presenter: Christina Teng, Scientia Clinical Research, Australia Abstract Title: IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): results from a phase 1 study Abstract No: 720MO Session Type and Title: ESMO 2024-Mini oral session 2: Gynecological cancers Presentation Time: Sunday, September 15, 2024, 15:45-15:50 CEST Presenter: Jin Shu, Chongqing University Affiliated Cancer Hospital WCLC: Posters Abstract Title: Neoadjuvant Chemoimmunotherapy for Potentially Resectable IIIA/IIIB NSCLC: Survival Updates and Predictive Effect of MRD Abstract No: EP.08D.01 Session Type and Title: E-Poster Presentation Time: Saturday, September 7, 2024 at 11:58-11:59 AM PDT Presenter: First Hospital of Jilin University, K. Ma Abstract Title: Safety and Efficacy of Sintilimab Combined with Anlotinib in Patients with KRAS-Mutant Advanced Non-Small Cell Lung Cancer Abstract No.: P4.11E.10 Session Type and Title: E-Poster Presentation Time: Monday, September 9, 2024 at 6:30 PM PDT Presenter: Peking University Shenzhen Hospital, F. Wang ESMO: Posters Abstract Title: First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study Abstract No: 574P Session Type and Title: ESMO 2024-Poster Presentation Time: Monday, September 16, 2024 CEST Presenter: Zhen Yu Lin, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Abstract Title: Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: results from a Phase 1 study Abstract No: 576P Session Type and Title: ESMO 2024-Poster Presentation Time: Monday, September 16, 2024 CEST Presenter: Jifang Gong, Peking University Cancer Hospital Abstract Title: Hepatic Artery Infusion Chemotherapy (HAIC) Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Initial Unresectable Hepatocellular Carcinoma (HCC) in Patients with Child-Pugh B Liver Function: A prospective study Abstract No.: 980P Session Type and Title: Hepatocellular carcinoma (HCC) - Poster Presentation Time: Monday, September 16, 2024 Presenter: Tianjin Medical University Cancer Institute & Hospital, Huikai Li Abstract Title: Hepatic arterial infusion chemotherapy combined with Sintilimab and regorafenib as adjuvant therapy for colorectal liver metastasis patients with high risk of recurrent: a single-arm, Phase 2 study Abstract No.: 539P Session Type and Title: Colorectal cancer - Poster Presentation Time: Monday, September 16, 2024 Presenter: Fudan University Shanghai Cancer Center, Lu Wang Abstract Title: Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naïve EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results Abstract No: 1329P Session Type and Title: NSCLC, metastatic - Poster Presentation Time: Saturday, September 14, 2024 Presenter: Jiangsu Province Hospital, Pei Ma Abstract Title: Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): a single-center, single-arm, Phase 2 trial Abstract No.: 1735P Session Type and Title: Sarcoma - Poster Presentation Time: Saturday, September 14, 2024 Presenter: Shandong Cancer Institute, Shandong Cancer Hospital, Zengjun Liu Abstract Title: Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter Phase 2 trial Abstract No.: 389P Session Type and Title: Breast cancer, metastatic - Poster Presentation Time: Monday, September 16, 2024 Presenter: Shandong Cancer Institute, Shandong Cancer Hospital, Huihui Li Trial in Progress Abstract Title: Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase 1b/2 clinical trial (FUNCTION) Abstract No.: 1475TiP Session Type and Title: Oesophagogastric cancer, Poster Presentation Time: Monday, September 16, 2024 Presenter: Henan Cancer Hospital, Bei-Bei Chen About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 11 products in the market, 3 new drug applications under the NMPA review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics